Global Agitation in Delirium Management Market Overview:
Global Agitation in Delirium Management Market is expected to grow at a significant rate during the forecast period 2026-2035, with 2024 as the base year.
Global Agitation in Delirium Management Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Agitation in Delirium Management involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Agitation in Delirium Management Market:
The Agitation in Delirium Management Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Agitation in Delirium Management Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Agitation in Delirium Management Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Agitation in Delirium Management market has been segmented into:
First-generation Antipsychotics
Second-generation Antipsychotics
Benzodiazepines
By Application, Agitation in Delirium Management market has been segmented into:
Oral
Intramuscular
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Agitation in Delirium Management market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Agitation in Delirium Management market.
Top Key Players Covered in Agitation in Delirium Management market are:
Teva Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Ltd.
Glenmark Pharmaceuticals Limited
Mylan N.V.
Fresenius Kabi AG
Novartis AG
Akorn Incorporated
Zydus Cadila
Pfizer
Inc.
BioXcel Therapeutics
Inc.
Takeda Pharmaceutical Company Limited
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Agitation in Delirium Management Market by Type
4.1 Agitation in Delirium Management Market Snapshot and Growth Engine
4.2 Agitation in Delirium Management Market Overview
4.3 First-generation Antipsychotics
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 First-generation Antipsychotics: Geographic Segmentation Analysis
4.4 Second-generation Antipsychotics
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Second-generation Antipsychotics: Geographic Segmentation Analysis
4.5 Benzodiazepines
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Benzodiazepines: Geographic Segmentation Analysis
Chapter 5: Agitation in Delirium Management Market by Application
5.1 Agitation in Delirium Management Market Snapshot and Growth Engine
5.2 Agitation in Delirium Management Market Overview
5.3 Oral
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral: Geographic Segmentation Analysis
5.4 Intramuscular
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Intramuscular: Geographic Segmentation Analysis
5.5 Others
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Agitation in Delirium Management Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 TEVA PHARMACEUTICAL INDUSTRIES LTD.
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
6.4 GLENMARK PHARMACEUTICALS LIMITED
6.5 MYLAN N.V.
6.6 FRESENIUS KABI AG
6.7 NOVARTIS AG
6.8 AKORN INCORPORATED
6.9 ZYDUS CADILA
6.10 PFIZER
6.11 INC.
6.12 BIOXCEL THERAPEUTICS
6.13 INC.
6.14 AND TAKEDA PHARMACEUTICAL COMPANY LIMITED
Chapter 7: Global Agitation in Delirium Management Market By Region
7.1 Overview
7.2. North America Agitation in Delirium Management Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 First-generation Antipsychotics
7.2.4.2 Second-generation Antipsychotics
7.2.4.3 Benzodiazepines
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Oral
7.2.5.2 Intramuscular
7.2.5.3 Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Agitation in Delirium Management Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 First-generation Antipsychotics
7.3.4.2 Second-generation Antipsychotics
7.3.4.3 Benzodiazepines
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Oral
7.3.5.2 Intramuscular
7.3.5.3 Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Agitation in Delirium Management Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 First-generation Antipsychotics
7.4.4.2 Second-generation Antipsychotics
7.4.4.3 Benzodiazepines
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Oral
7.4.5.2 Intramuscular
7.4.5.3 Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Agitation in Delirium Management Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 First-generation Antipsychotics
7.5.4.2 Second-generation Antipsychotics
7.5.4.3 Benzodiazepines
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Oral
7.5.5.2 Intramuscular
7.5.5.3 Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Agitation in Delirium Management Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 First-generation Antipsychotics
7.6.4.2 Second-generation Antipsychotics
7.6.4.3 Benzodiazepines
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Oral
7.6.5.2 Intramuscular
7.6.5.3 Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Agitation in Delirium Management Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 First-generation Antipsychotics
7.7.4.2 Second-generation Antipsychotics
7.7.4.3 Benzodiazepines
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Oral
7.7.5.2 Intramuscular
7.7.5.3 Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Agitation in Delirium Management Scope:
|
Report Data
|
Agitation in Delirium Management Market
|
|
Agitation in Delirium Management Market Size in 2025
|
USD XX million
|
|
Agitation in Delirium Management CAGR 2025 - 2032
|
XX%
|
|
Agitation in Delirium Management Base Year
|
2024
|
|
Agitation in Delirium Management Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Limited, Mylan N.V., Fresenius Kabi AG, Novartis AG, Akorn Incorporated, Zydus Cadila, Pfizer, Inc., BioXcel Therapeutics, Inc., and Takeda Pharmaceutical Company Limited.
|
|
Key Segments
|
By Type
First-generation Antipsychotics
Second-generation Antipsychotics
Benzodiazepines
By Applications
Oral
Intramuscular
Others
|
